{"name":"Cessatech A/S","slug":"cessatech-a-s","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CT001","genericName":"CT001","slug":"ct001","indication":"Spinal muscular atrophy (SMA)","status":"phase_2"}]}],"pipeline":[{"name":"CT001","genericName":"CT001","slug":"ct001","phase":"phase_2","mechanism":"CT001 is a gene editing therapy that uses CRISPR-Cas9 to edit the SMN1 gene.","indications":["Spinal muscular atrophy (SMA)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxOUmQybk9TX2VZZTFLQVZuek1GNl9ZdUU2eFlSZTdVTWpqZEtLU3M2MnRVLURYT0VfWVFBMk95YTZEOHF0ZHhDZmFIcU0yWHBQUWY3TTQybWFVWmUyMkNBdlNGZ3l0TzhOSUJwZklSd0VONXFLd3RTSER4dDV5T1lkeUNrYnM4NTZzb1ZzVUFualNPV25vSXRIaXU4U2l4YjVkQUlQeE5MeWtpd3FqaHk4TVJwVWYyRS0yb0piNU9vZ2ZFUG1zdTJCWEdYbG1nQW1PNW9CWF9fWkEyY1Nwek9IenlzcERnTk96SzNxOWdvSDVGeUFXOXdZRFRrcndESU01SkNPMVN3X1pmQnQ5V1A1WllCaUhrRzJLSHVTdTY0cF80QQ?oc=5","date":"2025-09-24","type":"trial","source":"prnewswire.com","summary":"Moderate-to-Severe Acute Pain Market Anticipates Impressive Growth Trajectory at a CAGR of 14% During the Study Period (2020-2034) | DelveInsight - prnewswire.com","headline":"Moderate-to-Severe Acute Pain Market Anticipates Impressive Growth Trajectory at a CAGR of 14% During the Study Period (","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTFBSWDl4b2tOZ2JDRjVnRXdZelpYNm9YRTZLUkV1SXVsMWpuVlkyWmJYX19RMEJqMnRHSDJXbnBaMHhIWVJscDFKSGdGUlA1TGtLdmgwSGlqRFlDdw?oc=5","date":"2021-04-29","type":"pipeline","source":"TradingView","summary":"CESSA Stock Price and Chart — NGM:CESSA - TradingView","headline":"CESSA Stock Price and Chart — NGM:CESSA","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}